Side Effects
Does Ozempic Cause Kidney Stones? Facts, Myths, and Safe Next Steps
Ozempic can be a game-changer for weight and blood sugar management, but concerns about kidney health sometimes arise. One of the most common is: Does Ozempic cause kidney stones? Worries about dehydration, shifts in minerals like calcium or uric acid, and changes in kidney function are standard, and it’s easy to feel uncertain when you hear conflicting stories. That’s why this article What to Expect With Semaglutide? breaks down what’s fact, what’s myth, and what steps you can take to support your kidneys while using Ozempic safely.
To make those steps even easier, MeAgain’s GLP-1 app provides simple tools, such as hydration tracking, symptom logging, and reminders for labs and check-ins, so you can stay confident, supported, and focused on your health goals.
Table of Content
Does Ozempic Cause Kidney Stones?
Most people know that GLP-1 receptor agonist medications like Ozempic and Wegovy can cause relatively minor side effects like nausea and diarrhea. But new research confirms that more serious complications, like pancreatitis and kidney damage, are real.
It's essential to note that most individuals who use GLP-1 receptor agonist medications do not experience these side effects. It is necessary to be aware of all potential risks before using a medication. Here’s what the study suggests, plus what a weight loss physician wants you to know.
GLP-1 Drugs Linked to Mixed Health Risks in Nature Medicine Study
What the January 20 Nature Medicine study found about GLP-1 drugs and other outcomes
The authors analyzed records on more than two million people with diabetes who had used GLP-1 receptor agonists such as semaglutide. They reported lower risks for 42 outcomes, including dementia, cardiac arrest, and some cancers.
At the same time, the analysis showed a higher risk for 19 adverse outcomes, among them nausea, vomiting, gastroesophageal reflux, sleep problems, stomach cramps, pancreatitis, gastroparesis, acute kidney injury, and an increased incidence of kidney stones. The work is observational, so the pattern is association, not proof of cause, and confounding by indication and other factors can shape the results.
Does Ozempic Cause Kidney Stones? What the Clinical Evidence Shows
There is no precise, proven mechanism showing that semaglutide directly causes kidney stones. Randomized clinical trials of semaglutide and other GLP-1 medicines have not established a causal relationship with the development of new kidney stones (nephrolithiasis).
At the same time, the Nature Medicine signal and some postmarketing reports suggest that this question warrants attention. Trial data, regulatory labeling, and real-world safety reports should be reviewed together to judge the balance of risk for any individual.
How GLP-1 Drugs Affect Kidneys and the Risk of Acute Kidney Injury
The FDA prescribing information for semaglutide lists acute kidney injury and worsening of chronic renal failure as potential adverse reactions. Clinical trials and real-world evidence point in two directions.
On the benefit side, in people with type 2 diabetes and chronic kidney disease, semaglutide and similar agents have been linked to a lower risk of kidney failure and major kidney events, with one analysis showing about a 24 percent relative risk reduction for those endpoints.
Acute Kidney Injury Risk With GLP-1 Drugs Appears Low
On the harm side, several thousand reports of acute kidney injury associated with GLP-1 drugs appear in postmarketing data each year, with about 45 percent of those reports involving hospitalization and roughly 4 percent reporting fatal outcomes; many reports involved older GLP-1 agents such as liraglutide and exenatide.
A pooled analysis of seven trials did not find an elevated risk of acute kidney injury, suggesting that the absolute risk is low, likely well under one per thousand among people taking these agents.
What Usually Precipitates Kidney Injury While Using a GLP-1 Drug
Most reported kidney injuries occur early, within the first two months of starting therapy or during dose escalation. Dehydrating side effects, such as persistent vomiting and poor oral intake, commonly precede these events. Concomitant use of diuretics and other medications that alter fluid and electrolyte balance can increase risk.
Peter Drucker and others have observed that many AKI reports are tied to not eating or drinking; Drucker told clinicians to contact patients who are not eating or drinking for 24 to 36 hours.
Could Indirect Factors Linked to GLP-1 Use Raise the Chance of Kidney Stones
Yes. Low urine volume is the single strongest modifiable risk factor for stone formation. Persistent nausea, vomiting, or inadequate fluid intake while starting or escalating a GLP-1 drug can reduce urine output and increase the concentration of stone-forming ions, thereby increasing the risk of calcium or uric acid stones.
Rapid weight loss and significant dietary shifts can alter urinary chemistry, sometimes increasing urinary oxalate or uric acid and promoting crystallization. Severe malabsorption after intestinal surgery is a known driver of oxalate stones; GLP-1 therapy is not the same as bariatric surgery, but marked changes in diet or intestinal transit could alter absorption in ways that matter for some people.
How Common Are Pancreatitis and Kidney Damage While Taking Ozempic
Both risks are low. Reported pancreatitis with GLP-1 therapy has generally been rare, usually under one percent in observational series. Reports of kidney damage severe enough to require hospitalization exist, but are uncommon; many are case reports or come from older drugs in the class. Still, clinicians and patients should remain vigilant for warning signs and report any suspected adverse events through the usual safety channels.
Practical Steps for Patients and Clinicians to Reduce Kidney Stone and Kidney Injury Risk
Review baseline kidney function with serum creatinine and estimated glomerular filtration rate before starting or when increasing the dose.
Ask about prior kidney stones, gout, chronic kidney disease, diuretic use, or medications such as NSAIDs that can affect kidney perfusion.
Start at the recommended low dose and escalate as per guidance. Counsel patients that the first week is when nausea and reduced intake are most likely.
Emphasize hydration. Maintain regular fluid intake, and seek medical care if vomiting or poor intake persists for more than a day.
Stop or adjust diuretics when clinically appropriate, and monitor electrolytes and kidney function early in therapy if dehydration or other risks occur.
Advise urgent evaluation for severe flank pain, blood in the urine, scant urine output, swelling, or severe abdominal pain.
Review the Ozempic prescribing information, recent trial data, and postmarketing safety reports when making individualized decisions.
Related Reading
• Why Am I So Hungry on Wegovy
• What Should I Expect the First Week of Wegovy
• Zepbound vs Wegovy Side Effects
• Wegovy vs Mounjaro Side Effects
• Wegovy vs Saxenda Side Effects
• Why Does Mounjaro Cause Diarrhea
• Why Does Mounjaro Cause Burping
• Why Am I Still Hungry on Mounjaro
• Does Wegovy Make You Tired
• Can Wegovy Cause Sulfur Burps
• Can Wegovy Cause Yeast Infection
Does Ozempic Benefit Chronic Kidney Disease?
Ozempic, a weekly semaglutide injection, acts on GLP-1 receptors to boost insulin release when glucose is high and to slow gastric emptying. This lowers fasting and post-meal blood sugar levels and also reduces appetite and calorie intake, resulting in steady weight loss.
For people with type 2 diabetes, better glycemic control and sustained weight loss reduce the metabolic stress on blood vessels and kidney filtering cells, which is directly linked to slower kidney injury when parameters remain improved over months of therapy. Ask your clinician about target A1C and weight goals while on semaglutide, so that labs and doses remain aligned with your changing needs.
Why Type 2 Diabetes Leads to Kidney Damage and How Quickly It Can Start
High blood sugar damages the tiny blood vessels and filtering structures in the kidneys. Initially, there may be no symptoms; damage can begin five to ten years before it is noticed.
Many people with type 2 diabetes show a measurable decline in estimated glomerular filtration rate within two to five years after diagnosis, and albuminuria often appears early as a warning sign of kidney stress. Regular urine albumin and eGFR checks can detect these changes, allowing interventions to begin before more severe loss occurs.
FLOW Trial Results: Semaglutide and Kidney Outcomes in People with Diabetes
The FLOW trial, conducted by Novo Nordisk, enrolled approximately 3,500 individuals with type 2 diabetes and chronic kidney disease to assess the effects of semaglutide versus placebo on kidney outcomes. The trial reported a 24 percent reduction in kidney disease events, a 20 percent reduction in all-cause mortality, and an 18 percent reduction in major cardiovascular events.
These findings support the idea that semaglutide improves blood sugar, weight, and cardiovascular risk, and that those improvements translate to fewer kidney failures and deaths in this population. The trial treated semaglutide as a metabolic therapy with secondary benefits for the kidneys, rather than as a primary kidney drug.
Semaglutide Effects on Kidney Markers in People Without Diabetes
Significant obesity and cardiovascular outcome studies of once-weekly semaglutide 2.4 milligrams have added data on kidney outcomes in people without diabetes. A large trial involving nearly 18,000 participants who received the higher dose found beneficial effects on kidney-related endpoints, including a reduced number of deaths attributed to kidney disease, a lower need for chronic kidney replacement therapy, and a slower decline in estimated glomerular filtration rate (eGFR).
Other obesity studies noted reductions in albuminuria and slower progression of chronic kidney disease among participants who lost weight and improved metabolic markers on semaglutide.
How Semaglutide May Protect the Kidneys: Mechanisms Explained
Several mechanisms likely link GLP-1 receptor agonists to better renal outcomes:
First, tighter glycemic control lowers glucose-mediated damage to glomeruli.
Second, weight loss reduces pressure on the kidneys and improves insulin resistance.
Third, semaglutide frequently lowers systolic blood pressure, which reduces glomerular hypertension.
Fourth, trials report reductions in albuminuria, implying less injury to the filtration barrier.
Fifth, GLP-1 agents exert anti-inflammatory and anti-oxidative effects and may improve renal blood flow and natriuresis.
These pathways work together to blunt kidney decline in patients at risk
Can Ozempic Cause or Worsen Kidney Injury?
Reports of acute kidney injury have occurred but are uncommon. Most cases link to severe gastrointestinal side effects such as prolonged nausea, vomiting, or diarrhea that cause dehydration and pre-renal kidney injury.
In rare situations, AKI required dialysis. Because dehydration can precipitate kidney harm, clinicians advise stopping semaglutide and checking serum creatinine if patients develop persistent vomiting or diarrhea. The long-term consequences of AKI episodes tied to GLP-1 agonists remain unclear, so careful monitoring is prudent for people with moderate to severe CKD.
Does Ozempic Cause Kidney Stones or Increase the Risk of Kidney Stones?
Current evidence does not indicate a direct, consistent relationship between semaglutide and an increased risk of renal calculi. Weight loss itself can alter urinary chemistry and sometimes increase the risk for certain stone types.
Still, the main weight loss drugs linked to stone risk are fat absorption agents, such as orlistat, which can increase urinary oxalate and raise the likelihood of oxalate nephropathy. To reduce any potential stone risk while on GLP-1 therapy, stay well hydrated, monitor urinary symptoms, and get periodic labs if you have a history of kidney stones or CKD
Who Stands to Gain the Most for Kidney Health While Taking Ozempic
People with type 2 diabetes and early to moderate chronic kidney disease show the most apparent benefit in trials because semaglutide improves the three primary threats to kidney health:
Blood sugar
Blood pressure
Body weight
People with obesity or cardiovascular disease, who do not have diabetes, also exhibit favorable kidney signals in significant obesity and cardiovascular outcome studies, especially when albuminuria improves. Patients with advanced CKD or those prone to dehydration need closer follow-up and individualized dosing decisions.
Other GLP-1 Agonists and Kidney Effects
Liraglutide has been studied in several diabetes trials, which have noted slower progression of kidney disease, reduced albuminuria, and less decline in eGFR in individuals with type 2 diabetes.
These findings are consistent with a class effect of GLP-1 receptor agonists on metabolic and cardiorenal risk factors; agents differ in terms of dose, duration, and regulatory approval. None of these drugs is currently labeled as a primary therapy for kidney disease.
How Other Weight Loss Drugs Can Affect Kidney Health and Stone Risk
Non-GLP-1 weight loss agents can harm the kidneys in different ways. Orlistat and similar fat blockers can increase intestinal oxalate absorption, thereby increasing urinary oxalate levels and potentially raising the risk of oxalate nephropathy and kidney stones.
Some older appetite suppressants may alter kidney perfusion or interact with other medications used in CKD. When selecting a weight loss medication, discuss your history of kidney stones, baseline eGFR, and urine studies with your clinician so they can choose the safest option.
Monitoring and Practical Steps to Protect Kidney Health on Ozempic
Baseline eGFR and urine albumin to creatinine ratio, periodic labs after starting or increasing dose, symptom checks for persistent vomiting or diarrhea, and attention to hydration.
Reduce dose or pause treatment if creatinine rises or if you develop AKI risk factors. Ask your provider about drug interactions and whether you need tighter blood pressure targets while taking semaglutide.
Current Gaps and Ongoing Trials Testing Semaglutide for Kidney Disease
Ongoing studies continue to examine semaglutide across different stages of CKD and in more diverse populations. FLOW was a significant step, but trials that include populations at the highest risk, longer follow-up, and head-to-head comparisons with other kidney-protective strategies are still underway.
Researchers are also probing exact renal mechanisms and whether GLP-1 benefits persist after stopping therapy, so clinicians must weigh current evidence while staying alert for new trial results
Related Reading
• Can Ozempic Cause Muscle Pain
• Does Semaglutide Increase Heart Rate
• Does Semaglutide Cause Bruising
• Does Ozempic Cause Hiccups
• Does Wegovy Cause Insomnia
• Does Ozempic Cause Hair Loss
• Does Ozempic Cause Tooth Decay
• Can Ozempic Cause Gallbladder Issues
• Does Ozempic Make You Tired
• Can Ozempic Cause Muscle Pain
Download our GLP-1 app to Turn Your Weight Loss Journey into Your Favorite Game.
MeAgain turns the daily work of safe weight loss into a game. A friendly capybara nudges you to hit protein, fiber, water, and exercise targets. Log meals, track symptoms, and store photos on a Journey Card so you keep a record of each milestone. The app also sends medication reminders and allows you to share your progress with your clinician, making coordination simple.
Choosing and Starting Ozempic Wegovy or Mounjaro: What to expect and how to begin
Discuss with your prescriber which drug is best suited for your health, goals, and other medications. Start at the low dose your clinician prescribes and follow the titration plan to reduce nausea and other side effects.
Expect appetite suppression, some gastrointestinal upset, and slower adaptation during the first weeks. Check baseline labs, including kidney function, if you have risk factors. Keep a symptom log and report severe nausea, vomiting, dizziness, or reduced urine output to your clinician right away.
Protecting Muscle While Losing Weight on GLP-1 Therapy
Rapid weight loss can result in the loss of both lean mass and fat. Prioritize protein at every meal and add resistance training to preserve strength. Aim for higher protein intake relative to your body weight and include complete proteins and fortified plant sources when needed. Use MeAgain to set daily protein targets and track your strength sessions, allowing you to see progress in both weight and muscle performance.
Preventing Severe Constipation and Other Gut Issues
Constipation is common when eating patterns and gut motility change. Gradually increase your fiber intake to 25 to 35 grams per day, spread it evenly across meals, and pair it with adequate fluid intake. If stool becomes hard, start with gentle osmotic agents or a stool softener after consulting with your provider.
Watch for signs of bowel obstruction, such as severe pain or inability to pass gas, and log any recurring GI symptoms in MeAgain so your clinician can adjust medications or recommend testing.
Does Ozempic Cause Kidney Stones and What Raises the Risk
Direct proof that Ozempic causes kidney stones is limited. There are plausible pathways that may increase the risk of kidney stones for some individuals. Dehydration resulting from nausea or reduced fluid intake can cause the urine to become concentrated and promote stone formation. Rapid weight loss and specific dietary shifts can increase urinary oxalate levels, which contribute to the formation of calcium oxalate stones.
Changes in urine pH and increased uric acid levels during rapid fat breakdown can increase the risk of uric acid stones. Acute kidney injury from severe vomiting or low blood pressure has been reported with some GLP1 medications, which can complicate kidney function and stone risk. Monitor for signs of renal colic, severe flank pain, blood in the urine, or reduced urine output, and seek testing if you notice any of these symptoms.
Practical Steps to Lower Kidney Stone Risk While on GLP-1 Medication
Hydrate to keep urine pale and frequent. Maintain adequate dietary calcium with meals to reduce oxalate absorption and limit high-oxalate foods, such as spinach, nuts, and beet greens, if you have a history of stones. Cut excess sodium and avoid unnecessary high-dose vitamin C.
Maintain a balanced protein intake to protect your muscles without increasing urine acidity. If you have a history of nephrolithiasis or experience symptoms, consult your clinician for urine testing. MeAgain can remind you to drink water, log your symptoms, and track diet patterns that affect your urine chemistry.
How MeAgain Helps You Stay Healthy While Losing Weight
MeAgain links medication reminders to measurable habits that prevent common complications. Your capybara rewards you for meeting protein, fiber, and water goals, as well as for logging resistance workouts and bowel movements. The app flags potential issues, such as decreased urination, dizziness, or blood in the stool, so that you can contact your clinician sooner.
Use the Journey Card to save photos and data points at each milestone, then export a timeline to share during appointments. Download MeAgain and turn your weight loss journey into your favorite game.
Related Reading
• Does Ozempic Cause Eye Problems
• Zepbound Side Effects Muscle Pain
• What to Eat While on Wegovy
• How Long Do Side Effects of Wegovy Last
• Tirzepatide Side Effects Long-term
• What to Eat on Mounjaro
• How Much Water Should I Drink on Semaglutide
• Does Mounjaro Lower Cholesterol
• Does Mounjaro Affect Fertility
• How to Make Wegovy Work Better
• Wegovy Mental Side Effects